Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

NCT06059326 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: HSK7653 10 mg
DRUG: HSK7653 25 mg
DRUG: HSK7653 50 mg
DRUG: Placebo

Sponsor

Haisco Pharmaceutical Group Co., Ltd.